48
Participants
Start Date
January 10, 2023
Primary Completion Date
July 17, 2024
Study Completion Date
August 8, 2024
AP-PA02
Bacteriophage administered via inhalation
Placebo
Inactive Placebo administered via inhalation
New York Medical College, Hawthorne
University of Pennslyvania, Philadelphia
Georgetown University Hospital / Pulmonary Critical Care and Sleep Medicine, Washington D.C.
Johns Hopkins University School of Medicine, Baltimore
Virginia Commonwealth University (VCU), Richmond
Medical University of South Carolina, Charleston
Mayo Clinic/Pulmonary, Critical Care, and Sleep Medicine, Jacksonville
TecTum Medical Research, Inc., Hollywood
University of Miami, Miami
Southwest General Healthcare Center, Fort Myers
Velocity Clinical Research, Mobile
Vanderbilt University Medical Center, Nashville
University Hospitals of Cleveland Medical Center, Cleveland
University of Cincinnati - College of Medicine, Cincinnati
Mayo Clinic, Rochester
The University of Kansas Medical Center / Dept of Medicine, Kansas City
University of Texas Health Science Center at Tyler, Tyler
St. Lukes Hospital, Boise
Southern California Institute for Respiratory Diseases Cedars-Sinai West Tower, Los Angeles
Oregon Health & Science University, Portland
University of Washington Medical Center, Seattle
UCONN Health, Farmington
Rutgers Robert Wood Johnson Medical School, New Brunswick
Lead Sponsor
Armata Pharmaceuticals, Inc.
INDUSTRY